Last checked at 31 May 2017 07:00
31 May 2017 |
Futura Medical plc
("Futura" or "the Company")
Total Voting Rights
As at the date of this announcement, the Company's issued share capital consists of 120,658,682 ordinary shares with a nominal value of 0.2 pence each ("Ordinary Shares"), each carrying one voting right.
The Company does not hold any Ordinary Shares in Treasury. Therefore, the total number of voting rights is 120,658,682.
The above figure of 120,658,682 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For further information please contact:
Futura Medical plc |
|
James Barder, Chief Executive | Tel: +44 (0) 1483 685 670 |
Email to: james.barder@futuramedical.com | www.futuramedical.com |
N+1 Singer (Nominated Adviser and Broker) |
|
Aubrey Powell / Liz Yong Corporate Finance
| Tel:+44 (0) 20 7496 3000 |
For media enquiries please contact: |
|
Buchanan |
|
Mark Court / Sophie Cowles / Stephanie Watson | Tel: +44 (0) 20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com